Evidence map›Paper›PMID 25057448›Full record

ArticleOncoimmunology

Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse.

Takayuki Yoshimoto, Izuru Mizoguchi, Seiichiro Katagiri, Tetsuzo Tauchi, Jun-Ichi Furusawa, Yukino Chiba, Junichiro Mizuguchi, Junko H Ohyashiki, Kazuma Ohyashiki

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Takayuki YoshimotoDepartment of Immunoregulation; Institute of Medical Science; Tokyo Medical University; Tokyo, Japan.
Izuru MizoguchiDepartment of Immunoregulation; Institute of Medical Science; Tokyo Medical University; Tokyo, Japan.
Seiichiro KatagiriDepartment of Hematology; Tokyo Medical University; Tokyo, Japan.
Tetsuzo TauchiDepartment of Hematology; Tokyo Medical University; Tokyo, Japan.
Jun-Ichi FurusawaDepartment of Immunoregulation; Institute of Medical Science; Tokyo Medical University; Tokyo, Japan.
Yukino ChibaDepartment of Immunoregulation; Institute of Medical Science; Tokyo Medical University; Tokyo, Japan ; Department of Immunology; Tokyo Medical University; Tokyo, Japan.
Junichiro MizuguchiDepartment of Immunology; Tokyo Medical University; Tokyo, Japan.
Junko H OhyashikiDepartment of Molecular Oncology; Institute of Medical Science; Tokyo Medical University; Tokyo, Japan.
Kazuma OhyashikiDepartment of Hematology; Tokyo Medical University; Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tyrosine kinase inhibitors have dramatically improved the treatment of chronic myeloid leukemia. Recent evidence revealed that some patients with chronic myeloid leukemia can stop imatinib without relapse after achieving a complete molecular response. This review discusses the possible predictive markers to identify these patients who can stop imatinib without relapse.

Indexed as

chronic myeloid leukemiacytotoxic T lymphocytesimatinibimmunosurvellianceNK cellspredictive marker

Identifiers

PMID25057448
PMCPMC4091524

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.